Unleash Immuno Oncolytics Overview

  • Founded
  • 2015
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $3M
Latest Deal Amount
  • Investors
  • 4

Unleash Immuno Oncolytics General Information


Developer of oncolytic virus immunotherapy products designed to treat cancer. The company's immunotherapy products include UIO-512, which is an oncolytic virus designed for targeting both malignant cells and tumor-associated stroma cells, enabling patients to start cancer treatment more quickly, resulting in a better medical outcome.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 4320 Forest Park Avenue
  • Suite 304
  • Saint Louis, MO 63108
  • United States
+1 (314) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Unleash Immuno Oncolytics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 19-Feb-2018 $3M 000 Completed Generating Revenue
2. Seed Round 12-May-2016 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Unleash Immuno Oncolytics’s complete valuation and funding history, request access »

Unleash Immuno Oncolytics Executive Team (7)

Name Title Board Seat Contact Info
Daniel Katzman Founder, Chief Executive Officer & Board Member
Louis Cantolupo Chief Operating Officer
David Curiel Ph.D Co-Founder & Chief Scientific Officer
Marina Scuseria Advisor
Osvaldo Podhajcer Ph.D Lead Scientific Advisor
You’re viewing 5 of 7 executive team members. Get the full list »

Unleash Immuno Oncolytics Board Members (4)

Name Representing Role Since
Charles Bolten BioGenerator Board Member 000 0000
Lisandro Bril Axia Ventures Board Member 000 0000
Yasunari Kashihara Self Board Member 000 0000
To view Unleash Immuno Oncolytics’s complete board members history, request access »

Unleash Immuno Oncolytics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Unleash Immuno Oncolytics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oncolys BioPharma Corporation 000 0000 000000 0
Axia Ventures Venture Capital Minority 000 0000 000000 0
BioGenerator Venture Capital Minority 000 0000 000000 0
Cygnus Capital Accelerator/Incubator Minority 000 0000 000000 0
To view Unleash Immuno Oncolytics’s complete investors history, request access »